Skip to content

Intervention Study on the Changes of Intrinsic Capacity in Elderly People by Immunomodulatory Therapy

Intervention Study on the Changes of Intrinsic Capacity in Elderly People by Immunomodulatory Therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107884
Enrollment
Unknown
Registered
2025-08-20
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

low immune function

Interventions

intervention group:Thymalfasin injection

Sponsors

zhejiang hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
75 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.Age >= 75 years and <= 100 years; 2.Patients with multiple comorbidities have at least two chronic diseases among diabetes, hypertension, coronary heart disease, chronic renal insufficiency, and COPD.

Exclusion criteria

Exclusion criteria: 1.There was a case of organ or bone marrow transplantation. 2.Systemic autoimmune disease; 3.There are malignant blood tumors. 4.Having underlying diseases or being in an end-stage condition with an estimated survival time of less than 28 days; 5.Have participated in clinical studies of drugs or devices related to immune system regulation within the past 30 days (such as Xuebi Jing, Ushidutin, CRRT); 6.Have a history of allergy or intolerance to thymalfasin;

Design outcomes

Primary

MeasureTime frame
Laboratory blood indicators;

Countries

China

Contacts

Public ContactZiqing Ye

zhejiang hospital

bobby0571@163.com+86 571 8159 5220

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026